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Many drugs have potential to induce the expression of drug-metabolizing enzymes, particularly cyto-
chrome P450 3A4 (CYP3A4), in small intestinal enterocytes. Therefore, a model that can accurately
evaluate drug-mediated CYP3A4 induction is urgently needed. In this study, we overlaid Matrigel on the
human induced pluripotent stem cells-derived enterocyte-like cells (hiPS-ELCs) to generate the mature
hiPS-ELCs that could be applied to drug-mediated CYP3A4 induction test. By overlaying Matrigel in the
maturation process of enterocyte-like cells, the gene expression levels of intestinal markers (VILLIN,
sucrase-isomaltase, intestine-speciﬁc homeobox, caudal type homeobox 2, and intestinal fatty acid-binding
protein) were enhanced suggesting that the enterocyte-like cells were maturated by Matrigel overlay.
The percentage of VILLIN-positive cells in the hiPS-ELCs found to be approximately 55.6%. To examine the
CYP3A4 induction potential, the hiPS-ELCs were treated with various drugs. Treatment with dexa-
methasone, phenobarbital, rifampicin, or 1a,25-dihydroxyvitamin D3 resulted in 5.8-fold, 13.4-fold, 9.8-
fold, or 95.0-fold induction of CYP3A4 expression relative to that in the untreated controls, respectively.
These results suggest that our hiPS-ELCs would be a useful model for CYP3A4 induction test.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cytochrome P450 3A4 (CYP3A4) is a dominant drug-
metabolizing enzyme in the enterocytes. Because CYP3A4 con-
tributes to the ﬁrst-pass metabolism of many commercial drugs, it
is important to investigate the CYP3A4-mediated intestinalP3A4, cytochrome P450 3A4;
GF2, ﬁbroblast growth factor
receptor; hiPS-ELCs, human
e cells; IFABP, intestinal fatty
ox; PB, phenobarbital; PXR,
rodimer partner; SI, sucrase-
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Inc. This is an open access article umetabolism in order to improve oral drug bioavailability [1,2]. It is
known that the CYP3A4 expression in enterocytes can be induced
by various drugs, such as dexamethasone (DEX), phenobarbital
(PB), rifampicin (RIF), and 1a,25-dihydroxyvitamin D3 (VD3) [3,4].
The induction of CYP3A4 expression in the enterocytes by such
drugs might affect the pharmacokinetics of concomitant drugs
administered orally. Therefore, a model that could evaluate drug-
mediated CYP3A4 induction in the enterocytes would be useful
for drug discovery.
Caco-2 cells (a human colon carcinoma cell line) are widely used
as amonolayer model of human intestinal absorption of drugs [5,6].
However, it is difﬁcult to evaluate drug-mediated CYP3A4 induc-
tion by using a Caco-2 cell monolayer model because of the low
expression levels of CYP3A4 and pregnane X receptor (PXR, a nu-
clear receptor that is necessary for CYP3A4 induction) in Caco-
2 cells [7]. Although LS180 cells (a human colon carcinoma cell line)
are positive for PXR [8,9], the gene expression proﬁles of other
nuclear receptors, such as glucocorticoid receptor (GR), arender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
The antibodies used in this study.
Name of antibody Company Catalogue number
Anti-VILLIN antibody Abcam ab109516
Anti-sucrase isomaltase antibody Santa Cruz biotechnology sc-27603
Anti-CDX2 antibody Millipore AB4123
Donkey anti-rabbit IgG secondary antibody, Alexa Fluor 488 conjugate Thermo Fisher scientiﬁc A-11008
Donkey anti-goat IgG secondary antibody, Alexa Fluor 488 conjugate Thermo Fisher scientiﬁc A-11055
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knowledge, an in vitro model that can accurately evaluate drug-
mediated CYP3A4 induction in human enterocytes has not been
established.
Recently, several groups have reported that intestinal tissues
and organoids, which consist of all four intestinal cell types (paneth
cells, goblet cells, enterocytes, and enteroendocrine cells), could be
differentiated from human pluripotent stem cells in vitro [11e13].
However, because these intestinal tissues and organoids are
generated under 3-dimensional culture conditions, it would be
difﬁcult to generate a monolayer model using these intestinal tis-
sues and organoids. Therefore, it might be difﬁcult to apply these
intestinal tissues and organoids to drug absorption andmetabolism
studies. Although some researchers have demonstrated that
enterocyte-like cells (ELCs) could be generated under 2-
dimensional culture conditions from human pluripotent stem
cells, their drug-mediated CYP3A4 induction potency has not been
well characterized [14e18].
In this study, we overlaid Matrigel on the human induced
pluripotent stem cells-derived enterocyte-like cells (hiPS-ELCs) to
generate the mature hiPS-ELCs that could be applied to drug-
mediated CYP3A4 induction tests. To investigate whether the
overlaying Matrigel maturated the hiPS-ELCs, we analyzed the
expression levels of intestinal markers. Moreover, we performed a
drug-mediated CYP3A4 induction test in the hiPS-ELCs, Caco-2, and
LS180 cells.
2. Materials and methods
2.1. Human iPS cells culture
A human iPS cell line, Tic (provided by Dr. A. Umezawa, National
Center for Child Health and Development), was maintained on a
feeder layer of mitomycin C-treated mouse embryonic ﬁbroblasts
(Millipore) with ReproStem medium (ReproCELL) supplemented
with 10 ng/ml ﬁbroblast growth factor 2 (FGF2, KATAYAMA
CHEMICAL INDUSTRIES).
2.2. In vitro differentiation
Before the initiation of enterocyte differentiation, human iPS
cells were dissociated into clumps by using dispase (Roche) and
plated onto growth factor reduced BD Matrigel Basement Mem-
brane Matrix (BD Biosciences). These cells were cultured in the
MEF-conditioned medium for 2e3 days. The differentiation pro-
tocol for the induction of deﬁnitive endoderm cells was described
previously [19]. Brieﬂy, for the deﬁnitive endoderm differentiation,
human iPS cells were cultured for 4 days in L-Wnt-3A-expressing
cell-conditioned RPMI1640 medium (Sigma) containing 100 ng/ml
Activin A (R&D Systems), 1  GlutaMAX, 0.2% fetal bovine serum
(FBS), and 1  B27 Supplement Minus Vitamin A (Life Technolo-
gies). For the induction of intestinal cells, the deﬁnitive endoderm
cells were cultured for 4 days in the intestinal differentiation me-
dium (DMEM-High Glucose medium (Invitrogen) containing 10%
Knockout Serum Replacement (KSR, Invitrogen), 1% Non-EssentialAmino Acid Solution (NEAA, Invitrogen), Penicillin-Streptomycin
(P/S), 1  GlutaMAX, and 100 mM b-mercaptoethanol) supple-
mented with 5 mM 6-Bromoindirubin-30-oxime (BIO, Calbiochem)
and 10 mM N-[(3,5-diﬂuorophenyl) acetyl]-L-alanyl-2-phenyl-1, 1-
dimethylethyl ester-glycine (DAPT, Peptide Institute). And then,
these cells were cultured for 12 days in the intestinal differentiation
medium supplemented with 1 mM BIO and 2.5 mM DAPT. For the
induction of enterocyte-like cells, the intestine-like cells were
cultured for 5 days in L-Wnt-3A-expressing cell-conditioned in-
testinal differentiation medium containing 0.1 mM BIO, 1 mM DAPT,
2 mM SB431542 (Wako), and 250 ng/ml epidermal growth factor
(EGF, R&D systems). And then, these cells were overlaid with thin
growth factor reducedMatrigel (50 mg/cm2), and cultured for 5 days
in the intestinal differentiation medium containing 250 ng/ml EGF.
2.3. Caco-2 and LS-180 cell culture and differentiation
Caco-2 cells (ATCC, HTB-37) were cultured with Minimal
Essential Medium (MEM, Sigma) containing 10% FBS, 1% NEAA,
2 mM L-glutamine, and P/S. For differentiation of Caco-2 cells, Caco-
2 cells were cultured for 21 days after they reached conﬂuence. LS-
180 cells (ATCC, CL-187) were cultured with MEM containing 10%
FBS, 1% NEAA, 2 mM L-glutamine, and P/S.
2.4. RNA isolation and reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was isolated from Caco-2 cells, LS-180 cells, and hu-
man iPS cells and their derivatives using ISOGENE (NIPPON GENE).
cDNAwas synthesized using 500 ng of total RNAwith a Superscript
VILO cDNA synthesis kit (Invitrogen). Human Small Intestine Total
RNA (4 lots) was purchased from BioChain. Real-time RT-PCR was
performed with SYBR Green PCR Master Mix (Applied Biosystems)
using a StepOnePlus real-time PCR system (Applied Biosystems).
Relative quantiﬁcationwas performed against a standard curve and
the values were normalized against the input determined for the
housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). PCR primers sequences were obtained from qPrimerDe-
pot (http://primerdepot.nci.nih.gov/).
2.5. Flow cytometry
Single-cell suspensions of the hiPS-ELCs were treated with
1  Permeabilization Buffer (e-Bioscience), and then incubated
with the primary antibody, followed by the secondary antibody
(Table 1). Flow cytometry analysis was performed using a FACS LSR
Fortessa ﬂow cytometer (BD Biosciences).
2.6. CYP3A4 induction test
The hiPS-ELCs, Caco-2, and LS180 cells were treated with
250 mM dexamethasone (DEX, Wako), 1 mM phenobarbital (PB,
Wako), 20 mM rifampicin (RIF, Wako), or 100 nM 1a,25-
dihydroxyvitamin D3 (VD3, Cayman) for 48 h. Controls were
treated with DMSO (ﬁnal concentration 0.1%).
Fig. 1. Efﬁcient enterocyte differentiation from human iPS cells. (A) The procedure for differentiation of human iPS cells (Tic) into enterocyte-like cells (ELC) via deﬁnitive endoderm
cells is presented schematically. Details are described in the Materials and Methods section. (B) The gene expression levels of VILLIN, sucrase-isomaltase (SI), intestine-speciﬁc
homeobox (ISX), caudal type homeobox 2 (CDX2), and intestinal fatty acid-binding protein (IFABP) in undifferentiated human iPS cells (iPSCs), hiPS-ELCs (ELC), Matrigel over-
laid hiPS-ELCs (ELC-MG), LS180 cells (LS180), Caco-2 cells (Caco-2), and adult small intestine (Small Intestine) were examined by real-time RT-PCR. On the y axis, the gene
expression levels in the adult small intestine were taken as 1.0. (C) To evaluate enterocyte differentiation efﬁciency, the percentages of SI-positive, VILLIN-positive, and CDX2-
positive cells were measured by FACS analysis. All data are represented as means ± SD (n ¼ 3). *p < 0.05, **p < 0.01.
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Fig. 2. CYP3A4 induction potency in the hiPS-ELCs, Caco-2, and LS180 cells. (AeC) The
Matrigel-overlaid hiPS-ELCs (ELC-MG, A), Caco-2 cells (Caco-2, B), and LS180 cells
(LS180, C) were treated with solvent (DMSO), 250 mM dexamethasone (DEX), 1 mM
phenobarbital (PB), 20 mM rifampicin (RIF), or 100 nM 1a,25-dihydroxyvitamin D3
(VD3) for 48 h. The gene expression levels of CYP3A4 were examined by real-time RT-
PCR analysis. On the y axis, the gene expression levels in the DMSO-treated cells were
taken as 1.0. All data are represented as means ± SD (nS3). *p < 0.05, **p < 0.01
(compared with DMSO-treated cells).
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Statistical analysis was performed using the unpaired two-tailed
Student's t test.3. Results
3.1. Efﬁcient enterocyte differentiation from human iPS cells
To generate the hiPS-ELCs, human induced pluripotent stem
(iPS) cells were differentiated by sequential treatment with various
cytokines and compounds such as Activin A, BIO, DAPT, SB431542,
EGF, andWnt-3A according to our previous report [20]. To promote
their maturation, the hiPS-ELCs were overlaid with Matrigel
(Fig. 1A). The gene expression levels of intestinal markers, such as
VILLIN, sucrase-isomaltase (SI), intestine-speciﬁc homeobox (ISX),
caudal type homeobox 2 (CDX2), and intestinal fatty acid-binding
protein (IFABP), in the hiPS-ELCs were signiﬁcantly increased by
Matrigel overlay (Fig. 1B). In addition, the gene expression levels of
these markers in the hiPS-ELCs were higher than those in LS180
and Caco-2 cells. These results suggest that the hiPS-ELCs were
matured by Matrigel overlay. To examine the enterocytedifferentiation efﬁciency, the percentages of SI-positive, VILLIN-
positive, and CDX2-positive cells in the hiPS-ELCs were examined
by FACS analysis, and found to be approximately 25%, 55%, and 90%,
respectively (Fig. 1C). From these results, ELCs were efﬁciently
generated from human iPS cells by using our enterocyte differen-
tiation protocol.
3.2. CYP3A4 induction potential of the hiPS-ELCs, Caco-2, and
LS180 cells
To examine the drug-mediated CYP3A4 induction potency of the
hiPS-ELCs, the hiPS-ELCs were treated with DEX, PB, RIF, or VD3, all
of which are known as CYP3A4 inducers [21]. Treatment with DEX,
PB, RIF, or VD3 resulted in 5.8-fold, 13.4-fold, 9.8-fold, or 95.0-fold
induction of CYP3A4 expression relative to that in the untreated
controls, respectively (Fig. 2A). Because Caco-2 cells are the most
widely used enterocyte model, we also examined the CYP3A4 in-
duction potency in Caco-2 cells. Consistent with the previous re-
ports [8,9], we found that CYP3A4 expression was induced only by
VD3 treatment (Fig. 2B). In addition, we examined the CYP3A4
induction potency in LS180 cells. The CYP3A4 expression levels
were increased by PB, RIF, or VD3 treatment, but not by DEX
treatment (Fig. 2C). From these results, hiPS-ELC would be a more
suitable model for CYP3A4 induction testing than Caco-2 and
LS180 cells.
3.3. Gene expression analysis of nuclear factors
It is known that drug-mediated CYP3A4 induction is mainly
regulated by nuclear receptors [22], such as PXR, GR, farnesoid X
receptor (FXR), small heterodimer partner (SHP), and vitamin D
receptor (VDR). For example, it is known that CYP3A4 induction by
RIF treatment is mediated by PXR [23] and CYP3A4 induction by
VD3 treatment is mediated by VDR [4]. These facts suggest that
nuclear receptors play an important role in drug-mediated CYP3A4
induction. Therefore, we analyzed the gene expression levels of
intestinal nuclear receptors (PXR, GR, FXR, SHP, and VDR) in the
hiPS-ELCs (Fig. 3). The gene expression levels of PXR, GR, FXR, and
SHP in the hiPS-ELCs were signiﬁcantly higher than those in Caco-2
and LS180 cells. On the other hand, there was no signiﬁcant dif-
ference in the VDR expression level between the hiPS-ELCs and
LS180 cells. These results suggest that the gene expression pattern
of intestinal nuclear receptors in the hiPS-ELCs is more similar to
that in the adult small intestine than are the patterns of intestinal
nuclear receptor expression in the Caco-2 and LS180 cells (Fig. 4).
4. Discussion
In this study, we succeeded in promoting enterocyte differen-
tiation from human iPS cells by overlaying Matrigel. Moreover, we
found that hiPS-ELCs have drug-mediated CYP3A4 induction po-
tency (Fig. 2A). The hiPS-ELCs were matured by Matrigel overlay
(Fig. 1B). It is known that various cytokines and extracellular
matrices are included in Matrigel, such as insulin-like growth
factor-1 (IGF-1) and laminin [24]. It was reported that IGF-1 pro-
motes the proliferation of the small intestinal epithelium [25],
while laminin promotes differentiation and maturation in Caco-
2 cells [26,27]. It might be possible that IGF-1 and laminin play
important roles in the proliferation and maturation of hiPS-ELCs. In
addition, we succeeded in reducing the culture period (30 days) by
Matrigel overlay as compared with our previous report (34 days)
[20]. Such a reduction in the culture period could decrease costs
which is an important requirement for the generation of hiPS-ELCs.
The percentages of SI- and VILLIN-positive cells in the hiPS-ELCs
were approximately 25% and 55%, respectively, although the
Fig. 3. Gene expression analysis of nuclear receptors in the hiPS-ELCs. The gene expression levels of nuclear receptors (PXR, SHP, GR, VDR, and FXR) in undifferentiated human iPS
cells (iPSCs), Matrigel-overlaid hiPS-ELCs (ELC-MG), LS180 cells (LS180), Caco-2 cells (Caco-2), and adult small intestine (Small Intestine) were examined by real-time RT-PCR. On the
y axis, the gene expression levels in adult small intestine were taken as 1.0. All data are represented as means ± SD (n ¼ 3). *p < 0.05, **p < 0.01.
Fig. 4. Summary of this study. Because human iPS cell-derived enterocyte-like cells expressed intestinal nuclear receptors, such as pregnane X receptor (PXR), glucocorticoid
receptor (GR) and vitamin D receptor (VDR), vitamin D3 (VD3)-, phenobarbital (PB)-, rifampicin (RIF)-, and dexamethasone (DEX)-mediated CYP3A4 induction could be evaluated
by using human iPS cell-derived enterocyte-like cells. On the other hand, PB-, RIF-, and DEX-mediated CYP3A4 induction could not be observed in Caco-2 cells because these cells
were negative for PXR and GR. In addition, DEX-mediated CYP3A4 induction could not be observed in LS180 cells because these cells were negative for GR. These results suggest that
the enterocyte-like cells differentiated from human iPS cells are a more appropriate model for the evaluation of drug-mediated CYP3A4 induction in enterocytes than either Caco-2
or LS180 cells.
R. Negoro et al. / Biochemical and Biophysical Research Communications 472 (2016) 631e636 635percentage of CDX2-positive cells in the hiPS-ELCs was approxi-
mately 90% (Fig. 1C). It is known that CDX2 is a marker of immature
cells in the intestinal lineage [11], while SI and VILLIN are markersof mature cells in the small intestinal epithelium [28]. Therefore,
the percentages of intestinal markers in the hiPS-ELCs differed
largely from each other.
R. Negoro et al. / Biochemical and Biophysical Research Communications 472 (2016) 631e636636The hiPS-ELCs expressed nuclear receptors, such as PXR, GR and
VDR (Fig. 3). In contrast, Caco-2 cells expressed only VDR, and did
not express PXR or GR (Fig. 3). These nuclear receptors are necessary
for the CYP3A4 induction by drugs such as DEX (a GR agonist), PB (a
PXR agonist), RIF (a PXR agonist) and VD3 (a VDR agonist).
Consistently, DEX, PB and RIF treatments did not induce CYP3A4
expression in Caco-2 cells (Fig. 2B). On the other hand, LS180 cells
expressed PXR and VDR, but not GR. Therefore, CYP3A4 expression
in LS180 cells was induced by PB, RIF and VD3 but not by DEX
(Fig. 2C). In contrast to Caco-2 and LS180 cells, the hiPS-ELCs
expressed each of PXR, VDR, and GR. CYP3A4 expression in hiPS-
ELCs was induced by DEX, PB, RIF, and VD3. These results suggest
that hiPS-ELCs are a more appropriate model for drug-mediated
CYP3A4 induction than Caco-2 and LS180 cells (Fig. 4). However,
the fold-changes of CYP3A4 expression induced by PB, RIF, and VD3
treatment in hiPS-HLCs were still lower than those in LS180 cells.
The drug-mediated CYP3A4 induction potency of hiPS-HLCs would
be further enhanced by improving the enterocyte differentiation
method.
In this study, we have succeeded in generating the mature hiPS-
ELCs for use in the drug-mediated CYP3A4 induction test. Because
CYP3A4-mediated small intestinal metabolism plays an important
role in oral drug bioavailability, our hiPS-ELC model would be
useful for generating drugs that have a low risk of unexpected
drugedrug interactions.We believe that our hiPS-ELCmodel would
thus be useful for discovering safer and more selective drugs.
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